Press Release

Calidi Biotherapeutics Presents Data at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium

SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, presented pre-clinical data on their lead oncolytic virus candidate SNV1 (allogeneic…

February 13, 2020

Calidi Biotherapeutics Announces Abstract Acceptance For Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium

Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced the acceptance of an abstract for presentation at the ASCO-SITC Clinical…

February 3, 2020

Calidi Biotherapeutics Secures Series A Investments to Advance Manufacturing

SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced Series A investments from two South Korean firms to…

January 22, 2020

The Mitchell Thorp Foundation Selects Calidi Biotherapeutics CEO to Receive the Pillars of Hope Award

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that the CEO…

December 19, 2019

Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George Ng, Partner…

October 9, 2019

Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine

SAN DIEGO, CA / ACCESSWIRE / September 18, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that…

September 18, 2019

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA

SAN DIEGO, CA / ACCESSWIRE / August 29, 2019 / Calidi Biotherapeutics Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer announced today, the completion…

August 29, 2019

Calidi Biotherapeutics Announces the Appointment of Distinguished Biotech Innovator, Ewa Carrier, M.D., to Their Medical and Scientific Advisory Board

Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of a distinguished innovator in the field of cancer diagnosis…

July 25, 2019

Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field

SAN DIEGO, CA / ACCESSWIRE / July 10, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of stem cell-based delivery of oncolytic virus-based immunotherapies for cancer,…

July 10, 2019

Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board

SAN DIEGO (PRWEB) JUNE 03, 2019 – Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of Dr. Dmitriy…

June 3, 2019

Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board

SAN DIEGO, May 30, 2019 /PRNewswire/ — Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech…

May 30, 2019

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells

SAN DIEGO, May 28, 2019 /PRNewswire/ — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced their ongoing scientific collaboration with…

May 28, 2019

Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa

SAN DIEGO (PRWEB) APRIL 15, 2019 Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that Allan Camaisa, Calidi Biotherapeutics CEO,…

April 15, 2019

Calidi Biotherapeutics Launches Scientific and Medical Advisory Board

SAN DIEGO, Jan. 3, 2019 /PRNewswire-PRWeb/ — Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding of a scientific…

January 4, 2019

Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO

SAN DIEGO, May 24, 2018 — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced a focused effort to advance its…

January 1, 2019

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

SAN DIEGO, Nov. 6, 2018 — Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of cell-delivered oncolytic viruses for the treatment of cancer, today announced that data from…

November 6, 2018

Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses

SAN DIEGO, October 25, 2018 – Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a…

October 25, 2018